SARTORIUS (UNSP.ADS)/1/5 (SRT0) - Total Liabilities
Based on the latest financial reports, SARTORIUS (UNSP.ADS)/1/5 (SRT0) has total liabilities worth €5.98 Billion EUR (≈ $6.99 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SARTORIUS (UNSP.ADS)/1/5 (SRT0) asset resilience to evaluate the company's liquid asset resilience ratio.
SARTORIUS (UNSP.ADS)/1/5 - Total Liabilities Trend (2022–2025)
This chart illustrates how SARTORIUS (UNSP.ADS)/1/5's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of SARTORIUS (UNSP.ADS)/1/5.
SARTORIUS (UNSP.ADS)/1/5 Competitors by Total Liabilities
The table below lists competitors of SARTORIUS (UNSP.ADS)/1/5 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tempus AI, Inc. Class A Common Stock
NASDAQ:TEM
|
USA | $1.78 Billion |
|
Krka d. d
WAR:KRK
|
Poland | zł665.51 Million |
|
Masimo Corporation
NASDAQ:MASI
|
USA | $977.70 Million |
|
CSPC Innovation Pharmaceutical Co Ltd Class A
SHE:300765
|
China | CN¥3.54 Billion |
|
Chart Industries Inc
NYSE:GTLS
|
USA | $6.42 Billion |
|
Dixon Technologies (India) Limited
NSE:DIXON
|
India | Rs149.67 Billion |
|
ORIENT OVERSEAS INT.ADR/5
F:ORI
|
Germany | €4.26 Billion |
|
Menora Miv Hld
TA:MMHD
|
Israel | ILA69.86 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down SARTORIUS (UNSP.ADS)/1/5's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SARTORIUS (UNSP.ADS)/1/5 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SARTORIUS (UNSP.ADS)/1/5's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SARTORIUS (UNSP.ADS)/1/5 (2022–2025)
The table below shows the annual total liabilities of SARTORIUS (UNSP.ADS)/1/5 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €5.85 Billion ≈ $6.84 Billion |
-5.73% |
| 2024-12-31 | €6.21 Billion ≈ $7.25 Billion |
-11.20% |
| 2023-12-31 | €6.99 Billion ≈ $8.17 Billion |
+61.79% |
| 2022-12-31 | €4.32 Billion ≈ $5.05 Billion |
-- |
About SARTORIUS (UNSP.ADS)/1/5
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell cult… Read more